Department of Psychiatry and Behavioral Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Addiction Psychiatrist, Springwoods Behavioral Health, Fayetteville, Arkansas, USA.
Am J Addict. 2022 May;31(3):219-225. doi: 10.1111/ajad.13266. Epub 2022 Mar 3.
Comorbid anxiety is common among buprenorphine patients and may lead to poorer outcomes. This study aimed to examine the prevalence and impact of anxiety severity, measured by the State-Trait Anxiety Inventory (STAI) form Y-1 & Y2 scale, on treatment outcomes (retention and phase advancement) among outpatient buprenorphine-treated patients.
A retrospective chart review of 94 patients admitted to an outpatient buprenorphine treatment program was conducted. Patients were dichotomized into high and low severity groups based upon an STAI State Anxiety (S-Anxiety) and STAI Trait Anxiety (T-Anxiety) score ≥60 and <60, respectively. Associations of anxiety severity on successful phase advancement and retention during the first 90 days of treatment were assessed.
Twenty-one of 94 (22%) participants reported high S-Anxiety and had a significantly greater likelihood of phase advancement (OR = 12.80, 95% CI = [1.19, 136.71]) than those with low S-Anxiety. No significant associations were found between either S-Anxiety or T-Anxiety and treatment retention. Current alcohol use and UDS negative test results for THC or amphetamines were each associated with phase advancement. THC negative UDS test results were associated with 90-day treatment retention.
Contrary to prior reports, buprenorphine patients with higher state anxiety severity demonstrated similar retention and more rapid phase advancement than those with lower state anxiety severity.
To our knowledge, this is the first study to quantify current anxiety severity using the STAI scale and evaluate its impact on treatment outcomes among buprenorphine-treated patients.
共病焦虑在丁丙诺啡患者中很常见，可能导致预后较差。本研究旨在检查焦虑严重程度（通过状态-特质焦虑量表 [STAI] Y-1 和 Y2 量表测量）对门诊丁丙诺啡治疗患者治疗结果（保留和阶段进展）的患病率和影响。
对 94 名入组门诊丁丙诺啡治疗项目的患者进行回顾性图表审查。根据 STAI 状态焦虑（S-Anxiety）和 STAI 特质焦虑（T-Anxiety）评分≥60 和 <60，将患者分为高严重度和低严重度组。评估焦虑严重度对治疗前 90 天内成功阶段进展和保留的影响。
94 名参与者中有 21 名（22%）报告有高 S-Anxiety，并且比低 S-Anxiety 患者更有可能实现阶段进展（OR=12.80，95%CI=[1.19, 136.71]）。S-Anxiety 或 T-Anxiety 与治疗保留之间均无显著关联。目前的酒精使用和 UDS 对 THC 或安非他命呈阴性测试结果与阶段进展有关。THC 阴性 UDS 测试结果与 90 天治疗保留有关。
与先前的报告相反，丁丙诺啡患者的状态焦虑严重程度较高，其保留率和阶段进展速度与状态焦虑严重程度较低的患者相似。
据我们所知，这是第一项使用 STAI 量表量化当前焦虑严重程度并评估其对丁丙诺啡治疗患者治疗结果影响的研究。
